Quick Answer
Instil Bio, Inc. reported Cash and Equivalents of $6.64 million for fiscal year 2025.
Instil Bio, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $6.64M | -24.6% |
| 2024 | $8.80M | -4.2% |
| 2023 | $9.20M | -79.0% |
| 2022 | $43.72M | +16.3% |
| 2021 | $37.59M | -84.4% |
| 2020 | $241.71M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.80M | -12.9% | -24.5% |
| June 30, 2025 | $7.69M | +13.4% | -50.0% |
| March 31, 2025 | $15.37M | +180.2% | +74.5% |
| December 31, 2024 | $8.80M | -4.2% | +32.1% |
| September 30, 2024 | $6.66M | -27.0% | -1.7% |
| June 30, 2024 | $6.78M | -68.8% | +23.7% |
| March 31, 2024 | $5.48M | -79.9% | -40.4% |
| December 31, 2023 | $9.20M | -79.0% | +0.7% |
- Instil Bio, Inc. showed a decrease of -24.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Instil Bio, Inc.’s cash and equivalents has declined by 97.3% (from $241.71 million to $6.64 million).
- The most recent figure is from Instil Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: